CTMS

EClinical Solutions Market size to grow by USD 9.7 billion from 2022 to 2027, North America to account for 41% of market growth, Technavio

Retrieved on: 
Wednesday, March 6, 2024

NEW YORK, March 6, 2024 /PRNewswire/ -- The eclinical solutions market is expected to grow by USD 9.7 billion from 2022 to 2027.

Key Points: 
  • NEW YORK, March 6, 2024 /PRNewswire/ -- The eclinical solutions market is expected to grow by USD 9.7 billion from 2022 to 2027.
  • In addition, the momentum of the market will progress at a CAGR of  13.47% during the forecast period, according to Technavio Research.
  • This report offers an up-to-date analysis of the current market scenario, the latest trends and drivers, and the overall market environment.
  • The global rehabilitation equipment market size is estimated to grow by USD 3.67 billion at a CAGR of 4.44% between 2023 and 2028.

Lindus Health Launches "All-In-One Metabolic CRO" Offering to Accelerate and Enhance Metabolic Clinical Trials

Retrieved on: 
Tuesday, March 5, 2024

This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.

Key Points: 
  • This unique marriage of technology and services sets metabolic sponsors up to run faster, more patient-centric clinical trials.
  • "Our All-in-One Metabolic CRO offering is designed to streamline study activities at every stage of research.
  • Lindus carries a site team with extensive resumes in the metabolic study execution that cover roles across PIs, CRCs, and more.
  • Lindus Health's all-encompassing Metabolic CRO offering empowers metabolic disease sponsors to run more timely and successful clinical trials while enhancing patient experience.

Lokavant Introduces First Source-Agnostic Data Engine to Drive Better Clinical Trial Decision-Making and Improve Performance

Retrieved on: 
Wednesday, January 31, 2024

Lokavant , the clinical trial intelligence platform company, announces PRIZM™ Clinical Data Hub (CDH), the industry’s source-agnostic clinical data hub to aid decision-making and improve trial performance with predictive analytics.

Key Points: 
  • Lokavant , the clinical trial intelligence platform company, announces PRIZM™ Clinical Data Hub (CDH), the industry’s source-agnostic clinical data hub to aid decision-making and improve trial performance with predictive analytics.
  • The life sciences industry struggles to harness enough data to fuel AI for practical uses in clinical research.
  • All trial data is harmonized in PRIZM which fuels Lokavant’s platform to provide a centralized view of trial performance in real time.
  • The industry needs a reliable solution to distill and standardize all the various data sources to drive improved clinical trial decisions.

Lindus Health Introduces Bespoke "All-In-One CRO for Digital Therapeutics" Solution to Companies in the Space Streamline Clinical Trials

Retrieved on: 
Thursday, February 1, 2024

Lindus Health's new offering for the DTx market bundles the services of an experienced CRO in DTx.

Key Points: 
  • Lindus Health's new offering for the DTx market bundles the services of an experienced CRO in DTx.
  • This offering is intended to produce a true "one-stop-shop" experience for everything needed to run a DTx clinical trial.
  • Technology-driven recruitment services: Lindus Health employs a variety of different strategies to accelerate DTx trials.
  • Lindus Health's "All-In-One CRO" offering enables DTx companies to achieve study milestones faster through their tech-forward and patient-centric approach to executing clinical trials.

RealTime Software Solutions Reports Record Growth in 2023, Emerging as the Premier Clinical Trial Management Solution for Clinical Research Sites

Retrieved on: 
Wednesday, January 17, 2024

Stephen Johnson, CEO of RealTime Software Solutions, reflects on the landmark year, stating, "The previous year has been transformative for RealTime.

Key Points: 
  • Stephen Johnson, CEO of RealTime Software Solutions, reflects on the landmark year, stating, "The previous year has been transformative for RealTime.
  • This evolution is a testament to our team's commitment to improving clinical trial management with state-of-the-art eClinical solutions."
  • Exponential User Adoption: Adopted by over 3,000 clinical research sites worldwide, RealTime has experienced a rapid surge in user growth.
  • Collaborations with clinical research sites worldwide have contributed to the platform's widespread adoption and recognition as a global leader in clinical trial management solutions.

TransPerfect Life Sciences Releases Trial Interactive 10.5

Retrieved on: 
Tuesday, November 28, 2023

NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- TransPerfect Life Sciences , a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, announced the release of version 10.5 of its award-winning Trial Interactive eClinical platform.

Key Points: 
  • NEW YORK, Nov. 28, 2023 (GLOBE NEWSWIRE) -- TransPerfect Life Sciences , a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, announced the release of version 10.5 of its award-winning Trial Interactive eClinical platform.
  • Trial Interactive’s user-friendly document and trial management automation helps pharmaceutical, biotechnology, and CRO companies effectively streamline product development lifecycles.
  • A fully connected solution, Trial Interactive offers fast-to-implement and cost-effective solutions in a secure 21 CFR Part 11-compliant environment.
  • “This update of Trial Interactive gives sponsors even more real-time oversight, process automation, and ease of use, as well as a feature-rich mobile experience,” said Michael Smyth, Division President of TransPerfect Life Sciences Solutions.

TransPerfect Life Sciences Releases Trial Interactive 10.5

Retrieved on: 
Tuesday, November 28, 2023

NEW YORK, Nov. 28, 2023 /PRNewswire/ -- TransPerfect Life Sciences, a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, announced the release of version 10.5 of its award-winning Trial Interactive eClinical platform. This new version is a significant update and brings new benefits to sponsors, enabling them to further automate oversight for proactive and predictive trial management.

Key Points: 
  • NEW YORK, Nov. 28, 2023 /PRNewswire/ -- TransPerfect Life Sciences , a leading provider of services and technologies to support global clinical trials and product development for the biopharmaceutical industry, announced the release of version 10.5 of its award-winning Trial Interactive eClinical platform.
  • Trial Interactive's user-friendly document and trial management automation helps pharmaceutical, biotechnology, and CRO companies effectively streamline product development lifecycles.
  • A fully connected solution, Trial Interactive offers fast-to-implement and cost-effective solutions in a secure 21 CFR Part 11-compliant environment.
  • "This update of Trial Interactive gives sponsors even more real-time oversight, process automation, and ease of use, as well as a feature-rich mobile experience," said Michael Smyth, Division President of TransPerfect Life Sciences Solutions.

Calyx CTMS Select Delivers Robust Functionality for Small/Mid-sized Biopharma and CROs

Retrieved on: 
Monday, November 20, 2023

NOTTINGHAM, England and BILLERICA, Mass., Nov. 20, 2023 /PRNewswire/ -- Calyx, the eClinical and eRegulatory solutions and services provider relied on for solving complex data challenges in clinical research announces an offering for small and mid-sized (SMID) biopharmaceutical companies and CROs that delivers the reliability and global operational support of a proven Clinical Trial Management System (CTMS) with faster implementation times and at lower costs.

Key Points: 
  • CTMS Select is tailored to meet the needs, timelines and budgets of SMID organizations who don't need CTMS customization
    Calyx CTMS Select is a scalable, pre-configured, and validated solution with the rich features required for effective clinical trial management oversight and monitoring.
  • Based on Calyx's 25+ years of expertise supporting diverse trials, it is perfectly tailored to meet the needs, timelines, and budgets of SMID organizations that don't require CTMS customization.
  • Calyx CTMS Select can be implemented in as little as 6-8 weeks and includes out-of-the-box eTMF and EDC integrations and sophisticated features – such as comprehensive site payments – that are rarely included in solutions for smaller organizations.
  • Click here for more information on Calyx CTMS Select.

Calyx CTMS Select Delivers Robust Functionality for Small/Mid-sized Biopharma and CROs

Retrieved on: 
Monday, November 20, 2023

NOTTINGHAM, England and BILLERICA, Mass., Nov. 20, 2023 /PRNewswire/ -- Calyx, the eClinical and eRegulatory solutions and services provider relied on for solving complex data challenges in clinical research announces an offering for small and mid-sized (SMID) biopharmaceutical companies and CROs that delivers the reliability and global operational support of a proven Clinical Trial Management System (CTMS) with faster implementation times and at lower costs.

Key Points: 
  • Calyx CTMS Select is a scalable, pre-configured, and validated solution with the rich features required for effective clinical trial management oversight and monitoring.
  • Based on Calyx's 25+ years of expertise supporting diverse trials, it is perfectly tailored to meet the needs, timelines, and budgets of SMID organizations that don't require CTMS customization.
  • Calyx CTMS Select can be implemented in as little as 6-8 weeks and includes out-of-the-box eTMF and EDC integrations and sophisticated features – such as comprehensive site payments – that are rarely included in solutions for smaller organizations.
  • Click here for more information on Calyx CTMS Select.

Dr. Yooni Kim, Vice President of Clinical Services at Novotech, Delivers Keynote Address at Veeva Korea Summit

Retrieved on: 
Thursday, October 12, 2023

SEOUL, Korea, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Novotech , the leading Asia Pacific centred biotech CRO with global execution capabilities, announced today that Dr. Yooni Kim, Vice President of Clinical Services at Novotech, served as a keynote speaker at the Veeva Korea Summit this week in Seoul, Korea.

Key Points: 
  • SEOUL, Korea, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Novotech , the leading Asia Pacific centred biotech CRO with global execution capabilities, announced today that Dr. Yooni Kim, Vice President of Clinical Services at Novotech, served as a keynote speaker at the Veeva Korea Summit this week in Seoul, Korea.
  • During her keynote address, Dr. Kim underscored several key advantages that the Novotech Veeva Platform, including the Vault Suite, is providing to clients.
  • Enable Clinical Systems support services under one platform, provide rapid study set-up, and one set of accounts and contacts.
  • Its commitment to collaboration is evident in the 50 Leading Site Partnership agreements it has signed over the past three years.